Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Filings indexed 378 across all filing types
Latest filing 2024-12-13 Regulatory Filings
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal regulatory notice of the procedural steps for the meeting. Given it is a standard regulatory notification regarding corporate governance procedures, it fits best under the RNS category.
2024-12-13 Korean
[기재정정]주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from Clinomics regarding the setting of a record date for an Extraordinary General Meeting of shareholders. It is a formal notice of a corporate action (setting a record date) rather than a report itself, and it does not fit into specific categories like dividend announcements or proxy solicitations. Therefore, it is classified as a general regulatory filing.
2024-11-25 Korean
[기재정정]주주총회소집결의 (임시주주총회)
AGM Information Classification · 1% confidence The document is a regulatory filing from Clinomics regarding the 'Resolution to Convene a General Meeting of Shareholders' (specifically an Extraordinary General Meeting). It details the date, location, and agenda items, and includes a correction notice regarding the schedule. This type of document is a formal notice of a shareholder meeting, which falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides information to shareholders regarding an upcoming meeting.
2024-11-25 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) from Clinomics, specifically detailing a correction (정정신고) to a previously filed convertible bond issuance (전환사채권 발행결정). It outlines changes to maturity dates, interest payment schedules, and conversion periods. Since this document details changes to the company's capital structure and financing terms, it falls under the 'Capital/Financing Update' category.
2024-11-25 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for Clinomics Inc., covering the period from January 1, 2024, to September 30, 2024. It contains detailed business descriptions, financial data, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from Clinomics regarding the 'Adjustment of Conversion Price' for convertible bonds. It details the change in conversion price, the number of convertible shares, and the underlying calculation methodology based on market price fluctuations. This type of disclosure relates to capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2024-11-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.